Entacapone Augmentation for Schizophrenia

Entacapone Augmentation for Schizophrenia- A Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00192855

Enrollment

Registered

2005-09-19

Start date

2003-06-30

Completion date

2006-10-31

Last updated

2010-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

schizophrenia, negative symptoms, entacapone

Brief summary

This study is testing the hypothesis that Entacapone added to ongoing antipsychotic treatment can be beneficial in schizophrenic patients with negative symptoms.

Interventions

DRUGEntacapone

Entacapone 600mg BID

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* predominantly negative symptoms * stable on ongoing antipsychotic treatment

Exclusion criteria

* acute psychotic exacerbation * suicidal ideation * uncontrolled systemic disease

Design outcomes

Primary

Measure	Time frame
Improvement in specific rating scales during the study and after completion, compared to baseline.	Baseline and once a month untill end of study

Secondary

Measure	Time frame
Change in PANSS score.	Before and after intervention

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026